Francesco Giorgino MD, PhD
Professor of Endocrinology, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, Bari, ItalyFrancesco Giorgino is Professor of Endocrinology and Chairman of the Department of Precision and Regenerative Medicine and Ionian Area at the University of Bari Aldo Moro, Bari, Italy. He is also Chief of the Division of Endocrinology at the University Hospital Policlinico Consorziale in Bari. Professor Giorgino received his M.D. degree from the University of Bari Aldo Moro and his Ph.D. degree from the University of Naples Federico II, in Italy. After completing clinical training in endocrinology at the University of Catania, Italy, he worked at the Joslin Diabetes Center and Harvard Medical School in Boston, MA, USA, as a postdoctoral research fellow and visiting scientist (1990-1994).
Professor Giorgino has received scientific awards from various institutions, including the Juvenile Diabetes Research Foundation International (JDRF) Fellowship (New York, NY, USA), the Mary K. Iacocca Foundation Fellowship (Boston, MA, USA), the Glaxo-Wellcome Award from the European Association for the Study of Diabetes (EASD), the Aldo Pinchera and Cassano Awards from the Italian Society of Endocrinology, and the Alcmeone Award from the Italian Society of Diabetology. He has been the Italian Delegate in European Commission Cooperation in Science and Technology (COST) actions for diabetes, has been President of the Italian Society of Endocrinology (2019-2021), and is currently Senior Vice-President of the European Association for the Study of Diabetes.
He is or has been a member of the Editorial Boards for PLoS ONE, Journal of Endocrinology, Endocrinology, Journal of Endocrinological Investigation, Adipocyte, Acta Diabetologica, Cardiorenal Medicine, Diabetes Metabolism Research and Reviews¸ Endocrine, and Endocrine Research. He has published more than 300 original and review articles and has been an invited speaker at many national and international meetings. His research interests include the mechanisms of insulin resistance and beta-cell dysfunction in type 2 diabetes and the effects of diabetes drugs on pancreatic islets and the cardiovascular system. He has an H-index of 69 and 18,500 citations (Google Scholar).
Disclosures
Professor Giorgino reports the following:- Advisory Boards: AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune, Medtronic, NovoNordisk, Roche Diabetes Care, Sanofi
- Other Boards: Senior Vice-President of the European Association for the Study of Diabetes (EASD)/European Foundation for the Study of Diabetes (EFSD)
- Consultant: Eli Lilly, NovoNordisk
- Lectures, presentations, or educational events: AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Lifescan, Merck Sharp & Dohme, Medtronic, NovoNordisk, Roche Diabetes Care, Sanofi
- Research Support: Eli Lilly, Roche Diabetes Care
- Receipt of Medical Writing or Support for Statistical Analysis: AstraZeneca, Eli Lilly, NovoNordisk, Roche Diabetes Care, Sanofi